

Maya H Buch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6684185/publications.pdf>

Version: 2024-02-01

145
papers

12,120
citations

81839

39
h-index

28275

105
g-index

155
all docs

155
docs citations

155
times ranked

11779
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
4	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.5	659
5	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499.	3.8	498
6	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.5	456
7	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.5	394
8	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.5	270
9	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
10	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018, 7, 356.	1.0	215
11	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3038-3047.	6.7	191
12	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017, 13, 463-475.	3.5	175
13	Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2014, 371, 1781-1792.	13.9	169
14	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002, 100, 4550-4556.	0.6	152
15	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1906-1910.	0.9	147
16	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 305-317.	6.3	145
17	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. <i>Journal of Rheumatology</i> , 2003, 30, 2287-91.	1.0	139
18	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	0.5	123

#	ARTICLE	IF	CITATIONS
19	Defining refractory rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 966-969.	0.5	119
20	Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 17-33.	3.5	118
21	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
22	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
23	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. <i>Nature Medicine</i> , 2022, 28, 1256-1268.	15.2	105
24	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
25	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019, 71, 1812-1823.	2.9	89
26	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, 912-921.	0.9	77
27	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
28	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor ? blockade. <i>Arthritis and Rheumatism</i> , 2004, 50, 725-728.	6.7	73
29	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. <i>Arthritis and Rheumatology</i> , 2018, 70, 903-911.	2.9	65
30	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 886-890.	0.5	64
31	New therapies in the management of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 245-251.	2.0	61
32	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , 2014, 50, 59-66.	3.0	59
33	Anti-TNF Treatment in Rheumatoid Arthritis. <i>Current Pharmaceutical Design</i> , 2011, 17, 3141-3154.	0.9	58
34	Transforming clinical trials in rheumatology: towards patient-centric precision medicine. <i>Nature Reviews Rheumatology</i> , 2020, 16, 590-599.	3.5	56
35	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
36	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , 2017, 13, 503-510.	3.5	51

#	ARTICLE	IF	CITATIONS
37	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
38	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1195-1201.	0.5	48
39	Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. <i>Frontiers in Medicine</i> , 2019, 6, 45.	1.2	45
40	Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 288.	1.6	44
41	The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1169-1175.	0.5	41
42	Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 909-912.	0.5	39
43	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1400-1409.	0.9	39
44	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2017, 19, 239.	1.6	38
45	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 420-427.	0.5	37
46	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
47	Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1414-1422.	0.5	32
48	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , 2016, 55, 1177-1187.	0.9	31
49	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018, 4, e000799.	1.8	31
50	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-Tnl and NT-proBNP. <i>Rheumatology</i> , 2019, 58, 1221-1226.	0.9	31
51	Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. <i>RMD Open</i> , 2017, 3, e000394.	1.8	28
52	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	1.8	28
53	Sequential use of biologic therapy in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 321-329.	2.0	27
54	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. <i>RMD Open</i> , 2020, 6, e001392.	1.8	26

#	ARTICLE	IF	CITATIONS
55	Costimulation blockade in rheumatic diseases: where we are?. <i>Current Opinion in Rheumatology</i> , 2009, 21, 244-250.	2.0	25
56	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.0	25
57	Primary myocardial disease in scleroderma—a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. <i>Rheumatology</i> , 2017, 56, kew364.	0.9	23
58	Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , 2021, 60, 4048-4054.	0.9	23
59	Biomarkers in the Management of Scleroderma: An Update. <i>Current Rheumatology Reports</i> , 2011, 13, 4-12.	2.1	22
60	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis—results from the IDEA study. <i>Rheumatology</i> , 2016, 55, 2181-2190.	0.9	21
61	The 'Switch'™ study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 452.	0.8	20
62	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
63	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. <i>Arthritis and Rheumatism</i> , 2004, 50, 4072-4073.	6.7	19
64	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Postgraduate Medical Journal</i> , 2012, 88, 482-486.	0.9	19
65	Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 66-70.	1.5	19
66	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	1.6	19
67	Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 436.	0.7	18
68	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1344-1346.	0.9	18
69	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 342.	0.8	18
70	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. <i>Rheumatology</i> , 2021, 60, 2934-2945.	0.9	18
71	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020, 6, e001211.	1.8	17
72	Changes in the pharmacological management of rheumatoid arthritis over two decades. <i>Rheumatology</i> , 2021, 60, 4141-4151.	0.9	17

#	ARTICLE	IF	CITATIONS
91	Normal values and testâ€“retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle. <i>British Journal of Radiology</i> , 2019, 92, 20190143.	1.0	10
92	Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021, 7, e001621.	1.8	10
93	OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, 3679-3688.	0.9	10
94	Nonresponse to tumor necrosis factor antagonistsâ€“is there any point in re-treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 288-289.	3.2	9
95	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2894.	1.8	9
96	Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. <i>Rheumatology</i> , 2021, 60, 2040-2045.	0.9	9
97	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 61.	0.8	8
98	Cardiac magnetic resonance imaging for the detection of myocardial involvement in granulomatosis with polyangiitis. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1053-1062.	0.7	8
99	Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. <i>Rheumatology</i> , 2021, 60, 1216-1225.	0.9	8
100	Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 491-501.	0.7	7
101	The PREdictor of MAInutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021, 8, 651748.	1.2	7
102	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. <i>Clinical Rheumatology</i> , 2022, , 1.	1.0	7
103	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 101.	1.0	6
104	Towards an optimum strategy in rheumatoid arthritis. <i>Lancet, The</i> , 2012, 379, 1682-1684.	6.3	6
105	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e044765.	0.8	6
106	Safety of biologics in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 425-451.	0.3	5
107	Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. <i>Rheumatology</i> , 2017, 56, 58-67.	0.9	5
108	GP2015 as a promising therapy for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 477-481.	1.4	5

#	ARTICLE	IF	CITATIONS
109	Response to 'Correspondence to viewpoint 'Defining refractory rheumatoid arthritis' by Buch' by Roodenrijs et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e106-e106.	0.5	5
110	Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study. <i>Arthritis Research and Therapy</i> , 2018, 20, 266.	1.6	4
111	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. <i>Rheumatology</i> , 2020, 59, 899-900.	0.9	4
112	Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscle. <i>British Journal of Radiology</i> , 2020, 93, 20190931.	1.0	4
113	Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2596-2602.	0.9	4
114	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: an international collaborative scoping review. <i>Rheumatology</i> , 2022, 61, 3132-3148.	0.9	4
115	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients. <i>Scientific Data</i> , 2022, 9, 196.	2.4	4
116	The 'therapeutic window' and treating to target in rheumatoid arthritis. <i>Clinical Medicine</i> , 2013, 13, 387-390.	0.8	3
117	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1684-1686.	0.9	3
118	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. <i>Rheumatology</i> , 2016, 55, 2273-2275.	0.9	2
119	First pilot study of extracellular volume MRI measurement in peripheral muscle of systemic sclerosis patients suggests diffuse fibrosis. <i>Rheumatology</i> , 2022, 61, 1651-1657.	0.9	2
120	Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response. <i>Rheumatology</i> , 2019, 58, .	0.9	1
121	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e140-e140.	0.5	1
122	Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 127-132.	0.4	1
123	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. <i>RMD Open</i> , 2021, 7, e001962.	1.8	1
124	Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 557-573.	0.0	0
125	Use of gevokizumab for the treatment of Behçet's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 755-763.	0.5	0
126	Law of the Vital Few: Choosing Variables of Disease Activity in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2097-2098.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Response to Dr Bredemeier's letter. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e34-e34.	0.5	0
128	A1.52â€¦TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A22.1-A22.	0.5	0
129	O15â€¦Implantable loop recorder in systemic sclerosis over three years confirms incidental significant arrhythmia and suggests CMR and cardiac biomarker association. <i>Rheumatology</i> , 2018, 57, .	0.9	0
130	209â€¦Normalisation of the American College of Rheumatology provisional composite response index in systemic sclerosis numerator for baseline data offers a measure of magnitude of response: results from a real-life observational study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
131	O18â€¦The PREdictor of MALnutrition in Systemic Sclerosis (PREMASS) score: the first validated combined index predictive of future weight loss in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
132	O85â€¦Mapping between the American College of Rheumatology 20/50/70 and (change in) Disease Activity Score-28 in rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, .	0.9	0
133	191â€¦Effectiveness and safety of switch to rituximab biosimilar with rheumatoid arthritis. a single centre experience. <i>Rheumatology</i> , 2019, 58, .	0.9	0
134	OP0021â€¦PREDICTING SEVERE INFECTION IN REPEAT CYCLES OF RITUXIMAB AND EFFECTS OF HYPOGAMMAGLOBULINAEMIA FOR THE TREATMENT OF RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0
135	SAT0227â€¦MYOCARDIAL FIBROSIS IS ASSOCIATED WITH ANCA STATUS, ORGAN INVOLVEMENT AND DISEASE SEVERITY IN PATIENTSWITH GRANULOMATOSIS WITH POLYANGIITIS. , 2019, , .		0
136	O28â€¦Has modern UK management of RA led to a reduction in use of steroids and NSAIDs? 20-year data from the clinical practice research datalink. <i>Rheumatology</i> , 2020, 59, .	0.9	0
137	P115â€¦Quantitative MRI of muscles is different in rheumatoid arthritis patients compared to healthy controls. <i>Rheumatology</i> , 2020, 59, .	0.9	0
138	Response to: â€œCorrespondence on â€œCardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritisâ€™â€™ by Georgiadis et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-219926.	0.5	0
139	Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-42.	0.9	0
140	Efficacy of tumour-necrosis factor-inhibitor in moderate disease activity rheumatoid arthritis: sub-analysis of the â€œVEDERAâ€™ trial. <i>Rheumatology</i> , 2022, 61, 868-869.	0.9	0
141	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. <i>Blood</i> , 2010, 116, 2322-2322.	0.6	0
142	Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrhumdis-2021-221775.	0.5	0
143	P215â€¦In a treatment-naïve, early rheumatoid arthritis cohort, baseline ultrasound power Doppler synovitis and tenosynovitis are highly associated with remission when treated with first line etanercept + methotrexate (MTX) but not MTX alone. <i>Rheumatology</i> , 2022, 61, .	0.9	0
144	P214â€¦Classifiable early RA shows heterogeneous imaging features and potential means of stratification. <i>Rheumatology</i> , 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
145	P217 Describing the evolution of concordance/discordance between DAS28-ESR and ultrasound power Doppler synovitis in a treatment-naïve early RA cohort. Rheumatology, 2022, 61, .	0.9	0